Clinical Trials

575 enrolled

Triple Negative Breast Neoplasms

NCT03168880 2025-04-09

TNBC

720 enrolled

Triple Negative Breast Neoplasms

NCT04296175 2025-03-26

CITRINE

808 enrolled

Triple Negative Breast Neoplasms

NCT03671044 2025-03-21

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

657 enrolled

Triple Negative Breast Neoplasms

NCT06419621 2025-03-12

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

360 enrolled

Triple Negative Breast Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

882 enrolled 41 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT04799249 2024-08-01

PRESERVE 2

194 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02488967 2024-06-03

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

782 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05134194 2024-04-16

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Phase 3 Terminated

1 enrolled

Triple Negative Breast Neoplasms

NCT03281954 2024-04-08

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

1,550 enrolled

Triple Negative Breast Neoplasms

NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

242 enrolled 12 charts

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

441 enrolled

Triple Negative Breast Neoplasms

NCT05999149 2024-02-21

BCTOP-T-N01

424 enrolled

Triple Negative Breast Neoplasms

NCT05954442 2024-01-16

BCTOP-T-M03

203 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03197935 2023-10-26

IMpassion031

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT03002103 2023-04-26

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Phase 3 Suspended

420 enrolled

Triple Negative Breast Neoplasms

NCT02425891 2022-07-19

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

902 enrolled 27 charts 1 FDA

BreastCNSGastrointestinalGynecologic

Triple Negative Breast Neoplasms

NCT02201381 2022-07-18

METRICS

Phase 3 Withdrawn

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

622 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03055312 2021-01-28

SYSUCC-007

Phase 3 Terminated

36 enrolled

Triple Negative Breast Neoplasms

NCT02032277 2021-01-20

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

634 enrolled

Neoplasms, Triple Negative Breast Neoplasms

NCT04403529 2020-06-01

Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Phase 3 Unknown

200 enrolled